Spectrum Pharmaceuticals

Summary

Spectrum Pharmaceuticals, Inc.
TypePublic
IndustryPharmaceuticals
HeadquartersHenderson, Nevada, U.S.
Key people
Joseph Turgeon, Chief Executive Officer
RevenueDecrease US$109.33 million (2018)
Number of employees
Increase 235 (December 31, 2018)
Websitesppirx.com

Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.

Drugs

Spectrum develops and markets drugs for treatments in oncology.

Approved drugs

  • Fusilev (Levoleucovorin) for injection is a drug that was approved by the U.S. Food and Drug Administration in 2008 for the US; the drug had been on the market in a number of European countries.[citation needed]
  • Folotyn (pralatrexate) is an antifolate drug marketed for relapsed or refractory peripheral T-cell lymphoma.
  • Khapzory (levoleucovorin) (Disodium Levoleucovorin), for injection, a folate analog for three indications:
    • Rescue after high-dose methotrexate therapy in patients with osteosarcoma.
    • Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination.
    • The treatment of patients with metastatic colorectal cancer in combination with fluorouracil.
  • Zevalin (ibritumomab) is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including patients with rituximab-refractory follicular NHL. It is a CD-20 radio-antibody.[1]
  • Marqibo (Vincristine sulfate liposomes injection) is a sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo's approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. It was approved by the FDA in 2012.[2]
  • Beleodaq (belinostat) is an HDAC inhibitor for relapsed or refractory peripheral T-cell lymphoma.
  • Evomela (melphalan) is an alkalyating drug for multiple myeloma.[1]

In development

As of 2019, a number of drugs are investigated in clinical trials.[3]

  • Qapzola (apaziquone) is a synthetic bio-reductive prodrug intended for the treatment of non-invasive bladder cancer that is currently in Phase 3 studies. Allergan invested money in 2008 to help develop this medication further and bring it to the market.[4]
  • Rolontis (eflapegrastim) is in phase III trials for treatment of chemotherapy-induced neutropenia.[5]
  • Poziotinib is a quinazoline-based pan-HER inhibitor that blocks signaling through HER tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4). It is currently in phase II trials.

Spectrum terminated the development of Ozarelix, a luteinizing hormone releasing hormone antagonist for the treatment of benign prostatic hypertrophy in 2010.[6] Other previous drug candidates included ortataxel for the treatment of taxane-refractory tumors, and satraplatin for non-small cell lung cancer.

References

  1. ^ a b [1][dead link]
  2. ^ "Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders". Businesswire.com. 3 September 2013. Retrieved 2 June 2019.
  3. ^ "Search of: Recruiting, Not yet recruiting, Available Studies - spectrum pharmaceuticals - List Results". Clinicaltrials.gov. Retrieved 2 June 2019.
  4. ^ Marcial G (June 15, 2009). "Cancer drugs from Spectrum". Businessweek: 67.
  5. ^ "RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide - Full Text View". Clinicaltrials.gov. Retrieved 2 June 2019.
  6. ^ "Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy (BPH) as It Continues to Prioritize Its Portfolio Strategy". Businesswire.com. 27 January 2010. Retrieved 2 June 2019.

External links

  • Official website